Long‐term follow‐up of covered stent implantation for various coronary artery diseases. Issue 4 (17th February 2019)

• Record Type: Journal Article
• Authors: Hachinohe, Daisuke; Latib, Azeem; Laricchia, Alessandra; Iannopollo, Gianmarco; Demir, Ozan M.; Ancona, Marco B.; Mangieri, Antonio; Regazzoli, Damiano; Giannini, Francesco; Azzalini, Lorenzo; Mitomo, Satoru; Chieffo, Alaide; Montorfano, Matteo; Carlino, Mauro; Colombo, Antonio
• Is Part Of: Catheterization and cardiovascular interventions. Volume 94:Issue 4(2019)
• Page Start: 571
• Page End: 577
• Publication Date: 2019-02-17
• Subjects: coronary artery aneurysm -- coronary artery perforation -- covered stent -- saphenous vein graft; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.28117
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: The aims of this study were to evaluate the long‐term clinical outcomes after coronary covered stent (CS) implantation and to compare the results according to the indications. Background: To date, data on the long‐term follow‐up of coronary CS are limited, and no studies have been conducted to compare outcomes on the basis of specific lesions treated. Methods: A total of 190 consecutive patients (212 lesions) implanted with CS and surviving until discharge between May 1997 and February 2017 were enrolled in this retrospective study. Clinical outcomes were evaluated and compared using the Gehan–Breslow–Wilcoxon test. Results: CS was mainly used for the treatment of a saphenous vein graft (SVG) (51.4%), followed by coronary artery perforation (CAP) (25.0%) and coronary artery aneurysm (CAA) (11.8%). The median follow‐up duration was 6.0 (interquartile range: 1.6–13.5) years. Target vessel myocardial infarction (MI), target vessel occlusion, target lesion revascularization, and stent thrombosis, frequently occurred in the early follow‐up period (7.3%, 16.6%, 21.5%, and 8.9% at 1 year, respectively) and continued to increase throughout the long‐term follow‐up (14.8%, 38.6%, 38.7%, and 17.8% at 10 years, respectively). Target vessel occlusion, target vessel MI, and ST were not identified in CAA with superiority to CAP (Gehan–Breslow–Wilcoxon p ‐value = 0.010, 0.047, and 0.046, respectively). SVG had a higher rate of target vessel occlusion than CAA ( p = 0.004). Conclusions: Clinical events after CS implantation frequently occurred in the early period and steadily increased in the long‐term period. CS implantation in CAA was associated with fewer adverse cardiac events and may lead to safe and acceptable outcomes. However, CS implanted in CAP and SVG are associated with a high risk of long‐term cardiac events.